Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2288 • ACR Convergence 2023
Scoping Literature Review and Focus Groups Interviews to Identify Candidate Domains for the SLE OMERACT Core Domain Set
Wils Nielsen¹, Vibeke Strand², Lee Simon³, Maya Desai⁴, Ioannis Parodis⁵, Alfred Kim⁶, Daniel Wallace⁷, Yashaar Chaichian⁸, Sandra Navarra⁹, Cynthia Aranow¹⁰, Meggan MacKay¹⁰, Kimberly Trotter¹¹, Oshrat Tayer-Shifman¹², Ali Duarte-Garcia¹³, Lai-Shan Tam¹⁴, Manuel Ugarte-Gil¹⁵, Guillermo Pons-Estel¹⁶, John Reynolds¹⁷, Mandana Nikpour¹⁸, Danae Papachristos¹⁹, Alberta Hoi²⁰, Alison Hendry²¹, Juanita Romero-Diaz²², Rosalind Ramsey-Goldman²³, Hanan Alrayes²⁴, Ibrahim Almaghlouth²⁵, Aarabi Thayaparan²⁶, Carolina Munoz-Grajales²⁷, Aaron Howe²⁸, Behdin Nowrouzi-Kia²⁸, Melanie Anderson²⁹, Dennisse Bonilla²⁹, Julian Thumboo³⁰, Marta Mosca³¹, Martin Aringer³², Sindhu Johnson³³, Aaron Drucker³⁴, Eric Morand³⁵, Ian Bruce³⁶ and Zahi Touma²⁸, ¹University of Toronto, Markham, ON, Canada, ²Stanford University, Portola Valley, CA, ³SDG LLC, West Newton, MA, ⁴OCAD University, Toronto, ON, Canada, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶Washington University School of Medicine, St. Louis, MO, ⁷Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁸Stanford University, San Mateo, CA, ⁹University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, ¹⁰Feinstein Institutes for Medical Research, Manhasset, NY, ¹¹University of Chicago, Chicago, IL, ¹²Meir Medical Center, Raanana, Israel, ¹³Mayo Clinic, Rochester, MN, ¹⁴The Chinese University of Hong Kong, New Territories, China, ¹⁵Universidad Cientifica del Sur, Lima, Peru, ¹⁶RELESSAR, Rosario, Argentina, ¹⁷University of Birmingham, Birmingham, United Kingdom, ¹⁸The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia, ¹⁹Mater Hospital, Brisbane, Australia, ²⁰Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Melbourne, Australia, ²¹Te Whatu Ora, Counties Manukau District, Middlemore Hospital, Auckland, New Zealand, ²²Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ²³Northwestern University, Chicago, IL, ²⁴Riyadh Military - Prince Soltan Military Medical City ( PSMMC ) - Olaya, Riyadh, Saudi Arabia, ²⁵King Saud University, Riyadh, Saudi Arabia, ²⁶Schroeder Arthritis Institute, Krembil Research Institute, Markham, ON, Canada, ²⁷UHN/TWH, Toronto, ON, Canada, ²⁸University of Toronto, Toronto, ON, Canada, ²⁹University Health Network, Toronto, ON, Canada, ³⁰Singapore General Hospital; Duke-NUS Medical School, Singapore, Singapore, ³¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ³²Faculty of Medicine TU Dresden, Dresden, Germany, ³³Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, ³⁴Women's College Hospital, Toronto, ON, Canada, ³⁵Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ³⁶University of Manchester, Manchester, United Kingdom
Background/Purpose: We established the OMERACT SLE Working Group in 2021 which includes over 150 members representing over 25 countries and 5 continents to develop a…
Abstract Number: 2305 • ACR Convergence 2023
Infection Vulnerability in Pregnant Women with and Without Systemic Lupus Erythematosus
Dr Hiba Khogali¹, Ghada Al‐Bluwi², Virgie Guy² and Ali Al Dhanhani³, ¹Tawam Hospital, Al Ain, United Arab Emirates, ²College of Medicine, UAE University, Al Ain, United Arab Emirates, ³UAE University, Al Ain, United Arab Emirates
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that predominantly affects women of childbearing age. Pregnant women with SLE have higher rates of…
Abstract Number: 2321 • ACR Convergence 2023
Does the Perspective of SLE Patients Match the Expert Opinion and Definitions of Remission and Low Disease Activity State? Prospective Analysis of 500 Patients from a Spanish Multicenter Cohort
CORAL Mourino Rodriguez¹, Jose-Maria Pego-Reigosa², Iñigo Rúa-Figueroa³, Francisco Rubino⁴, Iñigo Hernández-Rodríguez⁵, Raúl Menor-Almagro⁶, Esther Uriarte Isacelaya⁷, Eva Tomero Muriel⁸, TAREK CARLOS SALMAN MONTE⁹, MARIA IRENE CARRION BARBERA⁹, Maria Galindo¹⁰, Esther Rodriguez almaraz¹⁰, Norman Jiménez¹¹, Luis Ines¹² and Irene Altabas Gonzalez¹³, ¹Complejo Hospitalario Universitario de Vigo. IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain, ²Rheumatology, Hospital do Meixoeiro, Vigo, Spain, ³Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ⁴Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain, ⁵Hospital do Meixoeiro. Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁶Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, ⁷Hospital Universitario de Donostia, Donostia, Spain, ⁸Rheumatology, Hospital La Princesa, Madrid, Spain, ⁹Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ¹⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ¹¹IIRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute., Vigo, Spain, ¹²Centro Hospitalar e Universitario de Coímbra, Coimbra, Portugal, ¹³Complejo Hospitalario Universitario de Vigo, IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain
Background/Purpose: There is no information available regarding whether the patient's perception of disease activity aligns with current definitions of DORIS 2021 remission and Lupus Low…
Abstract Number: 2340 • ACR Convergence 2023
Multi-targeted Therapy Better in Achieving Complete Response in Lupus Nephritis: A Systematic Review and Meta-analysis
Omer Pamuk¹, Bisma Shaikh², Saif Khan³, Ali Abbas⁴, Sarah Abi Doumeth⁵ and sarfaraz Hasni⁶, ¹University Hospitals Cleveland Medical Center, Cleveland, OH, ²Jinnah Sindh Medical University, Karachi, Pakistan, ³College of Medical and Dental Sciences, Birmingham, United Kingdom, ⁴Alabama College of Osteopathic Medicine, Dothan, AL, ⁵Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, ⁶Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: The overall management of SLE and Lupus Nephritis (LN) has significantly improved over the last four decades.Recently great therapeutic strides have been made in…
Abstract Number: 2447 • ACR Convergence 2023
Interleukin-6 Activates Glial Cells and Induces Cognitive Dysfunction in Murine Neuropsychiatric Lupus
Joshua Reynolds¹, Michelle Huang¹, Myriam Meineck², Tamara Möckel², Andreas Schwarting² and Chaim Putterman¹, ¹Albert Einstein College of Medicine, Bronx, NY, ²University Medical Center of the Johannes Gutenberg University of Mainz, Mainz, Germany
Background/Purpose: Up to 50% of SLE patients experience neuropsychiatric involvement (neuropsychiatric lupus, or NPLSE) in the form of cognitive deficits, memory loss, depression, and anxiety.…
Abstract Number: 2502 • ACR Convergence 2023
Self-Reported Sleep Disorders Among Individuals with Systemic Lupus Erythematosus
Patti Katz¹, Maria Dall'Era², Jinoos Yazdany³ and Kaleb Michaud⁴, ¹University of California San Francisco, San Rafael, CA, ²University of California San Francisco, San Francisco, CA, ³University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Research in the general population has linked sleep disorders to poor outcomes such as lower pain thresholds, fatigue, cognitive impairment, depression, and cardiovascular disease…
Abstract Number: 2592 • ACR Convergence 2023
Trends, Sociodemographic and Clinical Factors Associated with Avascular Necrosis and Related Arthroplasties in Hospitalized Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Rashmi Dhital¹, Neha Singh², Brian Pedersen² and Christie M. Bartels³, ¹UC San Diego, San Diego, CA, ²University of California San Diego, San Diego, CA, ³University of Wisconsin, School of Medicine and Public Health, Madison, WI
Background/Purpose: Avascular necrosis (AVN) can be a debilitating complication of autoimmune diseases and steroid treatment, with a higher prevalence in systemic lupus erythematosus (SLE) (0.8-33%)…
Abstract Number: 0055 • ACR Convergence 2023
Elevated LINE-1 Expression in SLE Keratinocytes Leads to LINE-1 Reverse Transcriptase-dependent Type I Interferon Responses
Wenyan Miao¹, Daniel Rios¹, Mehrnaz Gharaee-Kermani², Craig Dobry², Artur Jaroszewicz¹, Cedric Arisdakessian¹, Enrique Garcia-Rivera¹, Nafeeza Hafeez¹, Brian Desrosiers¹, Jess Floro¹, Jared Steranka¹, Menachem Fromer¹, Dennis Zaller¹ and J. Michelle Kahlenberg², ¹Rome Therapeutics, Boston, MA, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Long Interspersed Element-1 (LINE-1) are retrotransposable DNA elements that make up ~17% of the human genome, and their role in health and disease is…
Abstract Number: 0156 • ACR Convergence 2023
Factors Associated with Adherence to Cervical Cancer Screening in Ethnically Diverse Women with Systemic Lupus Erythematosus
Sebastian Bruera¹, Savannah Bowman¹, Yinan Huang², Maria Suarez-Almazor³, Grace Lo¹, Elizabeth Chiao⁴, Maria A. Lopez-Olivo⁴ and Sandeep Agarwal¹, ¹Baylor College of Medicine, Houston, TX, ²Department of Pharmacy Administration, University of Mississippi School of Pharmacy, Oxford, MS, ³MD Anderson Cancer Center, Houston, TX, ⁴The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Women living with systemic lupus erythematosus (SLE) are at an increased risk of infections from human papillomavirus (HPV), and cervical cancer, especially women with…
Abstract Number: 0195 • ACR Convergence 2023
Assessing Cardiovascular Risk in Black and Latino Patients with Systemic Lupus Erythematosus
Glorielly Gonzalez¹, Zerai Manna², Alice Fike³, Jun Chu², sarfaraz Hasni² and Brian Dizon¹, ¹National Institute of Arthritis and Musculoskelatal and Skin Diseases, Bethesda, MD, ²Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Cardiovascular disease (CVD) is a major cause of mortality among patients with systemic autoimmune disease. Patients with systemic lupus erythematosus (SLE) exhibit accelerated cardiovascular…
Abstract Number: 0548 • ACR Convergence 2023
Clinical and Interferon Biomarkers to Exclude Imminent Autoimmune Disease in ANA Positive Individuals
Md Yuzaiful Md Yusof¹, Sabih Ul-Hassan¹, Zoe Wigston¹, Antonios Psarras², Jack Arnold¹, Lucy Carter³, Paul Emery⁴ and Ed Vital¹, ¹University of Leeds, Leeds, United Kingdom, ²Oxford University, Oxford, United Kingdom, ³University of Leeds, Hartlepool, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Many rheumatologists find it challenging to safely discharge "At-Risk" ANA-positive people at the first visit due to lack of cardinal signs and prediction tools.…
Abstract Number: 0566 • ACR Convergence 2023
Characterization of Disease Activity Using a Novel Physiologic Biomarker in Pediatric SLE
Sangeeta Sule, Olivia Lamanna, Kevin Jackson, Sun-Young Ahn, Tineer Ahmed and Julia Finkel, Children's National Hospital, Washington, DC
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex inflammatory disease involving many organ systems. To better understand and treat SLE, two phenotypes have been proposed.…
Abstract Number: 0584 • ACR Convergence 2023
Targeting Key Components of SLE Pathogenesis with the Multifaceted Immunomodulatory Properties of Cenerimod, a Selective S1P1 Receptor Modulator
Thomas Hoyler¹, Daniel Strasser¹, Ouali Berkani², Peter Cornelisse¹, Mark Murphy¹ and Marianne Martinic¹, ¹Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland, ²IDORSIA, Allschwil, Switzerland
Background/Purpose: In SLE, aberrant lymphocyte activation and autoantibody production result in deposition of immune complexes and contribute to tissue damage. Cenerimod, a highly selective S1P1…
Abstract Number: 0602 • ACR Convergence 2023
Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN-101) Reveals Non-Redundant Roles of T Cell Co-Stimulation Pathways in Systemic Lupus Erythematosus
Elizabeth Repash, Tiffany Blair, Amanda Enstrom, Lawrence Evans, Susan Debrot, Katherine Lewis, Armand Bankhead, Stanford Peng and Stacey Dillon, Alpine Immune Sciences, Inc., Seattle, WA
Background/Purpose: CD28 and inducible T cell costimulator (ICOS) play nonredundant roles in T cell activation and inhibiting these pathways can ameliorate an (auto)immune response. Systemic…
Abstract Number: 0786 • ACR Convergence 2023
A Retrospective Analysis of the Efficacy of the Euro-Lupus Nephritis Cyclophosphamide Regimen versus NIH Regimen in a South Carolina Lupus Nephritis Cohort
Anna Arar, Diane L. Kamen, Paul Nietert and Melissa Cunningham, Medical University of South Carolina, Charleston, SC
Background/Purpose: Manifestations of systemic lupus erythematous (SLE) vary in severity and presentation; lupus nephritis (LN) affects up to half of SLE patients and confers a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].